Sponsored · Video

PRA Health Sciences Leverages Technology & Data to Reinvent Clinical Trial Practices

PRA Health Sciences executives Sol Babani, Senior VP for Drug Development and Scott Schliebner, Senior VP for the Center for Rare Diseases and Digital Therapeutics, spoke at Biotech Showcase 2020 about the importance of small and emerging biotech companies who are on the leading edge of innovation in drug development. PRA is a global healthcare intelligence CRO with particular interest in offering their vast experience to early-stage biotechs with patient-focused approaches such as fully decentralized clinical trials and other cutting-edge methods to help developing biotechs reach their goals. PRA’s Center for Rare Diseases is a leader in the industry in leveraging technology, data, and patient focus in rare disease trials.

Trending on Xconomy